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Reversible Antibiotic Tolerance Induced in Staphylococcus aureus by
Concurrent Drug Exposure
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ABSTRACT Resistance of Staphylococcus aureus to beta-lactam antibiotics has led to increasing use of the glycopeptide antibi-
otic vancomycin as a life-saving treatment for major S. aureus infections. Coinfection by an unrelated bacterial species may ne-
cessitate concurrent treatment with a second antibiotic that targets the coinfecting pathogen.While investigating factors that
affect bacterial antibiotic sensitivity, we discovered that susceptibility of S. aureus to vancomycin is reduced by concurrent expo-
sure to colistin, a cationic peptide antimicrobial employed to treat infections by Gram-negative pathogens. We show that
colistin-induced vancomycin tolerance persists only as long as the inducer is present and is accompanied by gene expression
changes similar to those resulting frommutations that produce stably inherited reduction of vancomycin sensitivity
(vancomycin-intermediate S. aureus [VISA] strains). As colistin-induced vancomycin tolerance is reversible, it may not be de-
tected by routine sensitivity testing andmay be responsible for treatment failure at vancomycin doses expected to be clinically
effective based on such routine testing.
IMPORTANCE Commonly, antibiotic resistance is associated with permanent genetic changes, such as point mutations or acqui-
sition of resistance genes. We show that phenotypic resistance can arise where changes in gene expression result in tolerance to
an antibiotic without any accompanying genetic changes. Specifically, methicillin-resistant Staphylococcus aureus (MRSA) be-
haves like vancomycin-intermediate S. aureus (VISA) upon exposure to colistin, which is currently used against infections by
Gram-negative bacteria. Vancomycin is a last-resort drug for treatment of serious S. aureus infections, and VISA is associated
with poor clinical prognosis. Phenotypic and reversible resistance will not be revealed by standard susceptibility testing andmay
underlie treatment failure.
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Resistance to antimicrobial agents is now recognized as theprincipal challenge to efforts to control infectious diseases (1).
The bulk of such resistance is attributable to mutations that heri-
tably alter microbial sensitivity to therapeutic agents and which
can be transmitted linearly, and in some instances also laterally,
among populations of pathogens (2). Additionally, genes that in-
activate antibiotics or otherwise affect their actions can be trans-
mitted among microbes and can remain silent until they encoun-
ter a signal generated by the cognate antibiotic (for a recent review,
see reference 3).
Staphylococcus aureus is a Gram-positive bacterial pathogen
that colonizes 30% of healthy individuals and yet gives rise to a
wide variety of severe infections (4, 5). The epidemic spread of
S. aureus strains resistant to penicillins and other beta-lactam an-
tibiotics is a major threat (6) that is made more severe by the
increasingly frequent occurrence of heritable decreased suscepti-
bility of these bacteria to the glycopeptide antibiotic vancomycin,
commonly considered an antimicrobial agent of “last resort” for
treatment of S. aureus infections (7). Here, we report the existence
of an additional and previously unrecognized threat to vancomy-
cin efficacy: the induction of reversible vancomycin tolerance by
an antibiotic that may be administered for treatment of a coexist-
ing infection by an unrelated microbe. When investigating factors
that may affect S. aureus sensitivity to vancomycin, we discovered
that the bactericidal effects of this agent are reduced by concurrent
exposure to colistin, a cyclic polypeptide antibiotic used to treat a
variety of infections by Gram-negative bacteria. We demonstrate
that colistin-induced vancomycin tolerance persists only so long
as colistin is present and that induced vancomycin tolerance is
accompanied by altered gene expression and other phenotypic
properties characteristic of genetically stable VISA (vancomycin-
intermediate S. aureus) strains, which also show decreased sensi-
tivity to vancomycin. As colistin-induced resistance to vancomy-
cin is transient, it is not detectable by routinely used antimicrobial
susceptibility test procedures, and thus may account for treatment
failures observed in patients receiving vancomycin doses that are
expected on the basis of such testing to be clinically effective.
RESULTS
Screening for inducible antibiotic resistance. During a screen
for functional interactions between antibiotic combinations in a
community-associated methicillin-resistant S. aureus (CA-MRSA)
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strain, USA300 (Table 1), we observed that if cells were exposed to
colistin for 30 min, they were able to form colonies on otherwise-
restrictive concentrations of vancomycin (Fig. 1a). When
testing the ability of colistin to induce resistance against other
cell wall-active agents, we found that resistance was in-
duced against the glycopeptide teicoplanin which, like vancomy-
cin, prevents the synthesis of N-acetylmuramic acid and
N-acetylglucosamine polymers, which form the backbone of the
S. aureus cell wall (8). In contrast, no resistance was induced
against the membrane-active daptomycin (Fig. 1a). Our screen
also suggested other possible instances of antibiotic cross-toler-
ance; however, these were not studied further in the investigation
reported here (Fig. 1b; Table 1).
Colistin induces reversible vancomycin tolerance. We found
that exposure of USA300 to colistin for as little as 7 min resulted in
a 50% increase in the vancomycin MIC (from 1.1g/ml to 1.6g/
ml) (Fig. 2a). The colistin-induced elevation of the vancomycin
MIC resulted in a 5-fold increase in bacterial CFU at a vancomycin
concentration (i.e., 1.5 g/ml) that normally inhibits colony for-
mation (Fig. 2b); colistin itself had no effect on reproduction of
USA300 at this concentration (Fig. 2c). In both liquid and solid
media, colistin-induced tolerance of S. aureus to a normally inhib-
itory concentration of vancomycin required exposure to the in-
ducer prior to vancomycin treatment (Fig. 2a and d). Importantly,
vancomycin tolerance was dependent on the continued presence
of colistin and was reversed by culturing bacteria in colistin-free
medium for just 30 min prior to exposing them to vancomycin
(Fig. 2e).
Colistin-inducedgene expression resembles gene expression in
genetically stable VISA strains. To further investigate the mecha-
nism underlying the colistin-induced reversible tolerance ofS. aureus
to vancomycin, we first used DNA microarray analysis to profile the
effects of colistin on individual mRNAs. As phenotypic effects on
vancomycin sensitivity were evident after only 10 min of prior expo-
sure to colistin (Fig. 2), alterations in mRNA abundance were inves-
tigated at this time point. Using DNA probes for 2,572 S. aureus
genes, we identified 27 genes that were significantly (P 0.05) up-
regulated by colistin exposure (Table 2). Remarkably, among these
genes were 11 (shown in boldface type in Table 2) that have been
reported to be upregulated in clinically isolated VISA strains (repre-
sentation factor for overlap, 21.8; P 1.995e14), showing stably
inherited decreased susceptibility to vancomycin (MIC, 4 to 8g/ml)
(9, 10). Twenty-two of the 27 genes are known to be components of
either the VraSR (11) or the GraXRS (12) operons, both of which
have been implicated in genetically inherited multidrug resistance
(13, 14). Among the loci regulated by GraXRS is thedltABCDoperon,
which encodes proteins that decrease the negative charge at the bac-
terial cell surface and mediate the production and export of D-
alanyl-D-alanine residues on staphylococcal peptidoglycans targeted
by vancomycin (15).
Among the genes showing elevated expression on microarrays
as a result of colistin exposure were two known to mediate alter-
ations in S. aureus cell walls, mprF and dltB (16, 17). The rapidity
of the onset of vancomycin tolerance to colistin exposure led us to
investigate the temporal relationship between expression of these
genes and such tolerance. As seen in Fig. 3, both events were tightly
correlated temporally; elevation of mRNAs encoded by the mprF
and dtB genes were elevated after 10 min of colistin exposure (P
0.00012) and returned to preinduction levels by 30 min after colis-
tin was removed, consistent with our finding that continuous ex-
posure to colistin is needed for the maintenance of vancomycin
tolerance (Fig. 2d). These findings suggest that expression of these
two genes is useful as a rapidly assessed biomarker for colistin-
induced vancomycin tolerance.
The effects of colistin on gene exposure in S. aureus were bidi-
rectional. Sixty-nine of the 2,572 genes probed in our microarray
assays were significantly downregulated (P 0.05) after 10 min of
colistin exposure (see Table S1 in the supplemental material).
Among these was the saePQRS operon as well as the agrB and agrD
genes from the S. aureus quorum-sensing operon. Both operons
encode two-component systems that control the expression of
multiple virulence factors (18–20) and, accordingly, we observed
that 38% of the downregulated genes were indeed virulence genes.
Downregulation of virulence genes is commonly observed in
VISA strains (10, 21) and, possibly as a consequence, the virulence
of these strains can be attenuated (22).
Collectively, our gene expression data indicated that exposure
of USA300 to colistin induces a rapid and reversible transcrip-
tional response that bears striking similarities to the stably inher-
ited transcriptional changes observed in genetically mutated VISA
strains (10, 23–25). These alterations in gene expression were
highly specific and correlated temporally with elevated vancomy-
cin MICs.
VISA-like phenotypes of bacteria exposed to colistin. Earlier
work indicated that autolysis, which occurs in some S. aureus pop-
ulations during normal growth in culture, is reduced in VISA
strains (26), which also show both a decrease in the negative
charge at the cell surface (27) and an increase in cell wall thickness
(28). Exposure of non-VISA USA300 to colistin produced a de-
crease (P 0.007) (Fig. 4a) in autolysis comparable to that seen in
clinically isolated bacteria with the genetically inherited VISA
phenotype (26). Additionally, colistin-treated cells showed dra-
matically reduced binding to cytochrome c (10%  13% versus
TABLE 1 Screening of antibiotics that affect growth in the presence of inhibitory concentrations of other antibiotics
Test compound
Effect on growth after preexposure to inducer compound (target)a
Colistin
(membrane)
Vancomycin
(cell wall)
Teicoplanin
(cell wall)
Rifampin (DNA/
RNA synthesis)
Gentamicin
(protein synthesis)
Colistin     
Vancomycin     
Rifampin     
Ciprofloxacin   ND  
Tetracycline ND    
a, cells grew in the presence of a restrictive concentration of the tester antibiotic after preexposure to the inducer antibiotic;, no increased tolerance was observed with
preexposure to the inducer compound; ND, not determined.
Haaber et al.
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70% 6% in untreated cells [means standard deviations]; P
0.001) (Fig. 4b), which has been used to assay the decrease in
negative cell surface charge characteristic of VISA (27). However,
cell wall thickness, which commonly is increased in VISA strains,
was not altered in cells treated with colistin (22.81 nm 1.55 nm
versus 22.45 nm 1.43 nm in nontreated cells) (Fig. 4c).
Vancomycin tolerance regulated by cell wall stress operons.
The adjacent graXRS and vraFG operons together encode a five-
component system that along with the vraRS two-component reg-
ulatory system is central to S. aureus defense against vancomycin
and other agents that damage the bacterial cell wall (13, 14). The
VraFG transporter senses antimicrobial peptides (13) that activate
GraXRS-mediated transcription of the dlt operon and mprF,
which reduce the negative cell wall charge by increasing
D-alanylation of teichoic acids and increasing incorporation of
cationic phospholipid lysyl-phosphatidyl glycerol into the cyto-
plasmic membrane, respectively (16, 17). VraRS separately im-
pedes the actions of vancomycin by inducing genes that mediate
cell wall biosynthesis and the cell’s response to the stress of cell
wall damage (11, 14, 29). We found that deletion of vraR did not
significantly affect colistin-induced vancomycin tolerance. How-
ever, deletion of graR completely abolished such tolerance (Fig. 5),
directly demonstrating that a function of this gene is necessary for
colistin-mediated reduction of susceptibility to vancomycin in
USA300.
Reduced expression of the quorum-sensing and virulence reg-
FIG 1 Mitigation of antibiotic lethality by subinhibitory antibiotic concentrations in CA-MRSA USA300. (a) The ability of USA300 to form colonies at
inhibitory concentrations of the cell wall-active antibiotics vancomycin and teicoplanin as well as the cell membrane-active antibiotics colistin and daptomycin
was assayed after preexposure to sublethal doses of colistin. (b) The same experiment was carried out with preexposure to the ansamycin rifampin or the
fluoroquinolone ciprofloxacin, followed by plating on inhibitory concentrations of rifampin or vancomycin.
Colistin Induces a Reversible VISA Phenotype in MRSA
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ulator agr operon as well as that of the downstream regulon has
previously been observed in VISA strains (21, 30), but no func-
tional link has been made between agr and the VISA phenotype.
The ability of colistin to induce vancomycin tolerance in an agrC
deletion mutant indicated that the agr system is not required for
the phenotype (Fig. 5).
FIG 2 Colistin induces transient vancomycin tolerance in CA-MRSA USA300. (a) The MIC of vancomycin was determined in liquid medium for USA300 after
treatment with colistin (shaded bars) for the indicated times and compared to results with the untreated control (no fill). (b) The colony-forming ability of
USA300 on plates containing inhibitory concentrations of vancomycin was assayed for cells that had been preexposed to colistin for 30 min (shaded bars) and
compared to results with untreated cells (no fill). **, P  0.01, t test. (c) The colony-forming ability of USA300 on agar plates without antibiotics following
exposure () or no exposure () to colistin for 30 min. (d) Ten-minute preexposure of USA300 to colistin in liquid culture was compared to a nonexposed
control for the ability to grow on plates containing inhibitory concentrations of vancomycin. (e) USA300 was incubated with or without colistin for 30 min in
liquid culture. After removal of colistin from the medium and an additional 0 min or 30 min of incubation, the cultures were spotted on agar plates containing
vancomycin (VAN). All error bars represent standard deviations (n 3).
Haaber et al.
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DISCUSSION
The experiments reported here show that concurrent exposure to
antimicrobials used for treatment of an unrelated infection may
reversibly reduce susceptibility to antimicrobial drugs in the ma-
jor human pathogen S. aureus. In particular, exposure of S. aureus
to colistin reduces susceptibility to vancomycin and is associated
with altered gene expression and phenotypic changes, including
reduced autolysis and altered cell wall surface charge, that in VISA
strains lead to stably inherited decreases in susceptibility to van-
comycin resulting from mutation of one or more chromosomal
genes. Our results demonstrated that the colistin-induced pheno-
typic and temporal changes are mediated by induction of the
GraRS regulon, which previously was implicated also in the VISA
phenotype. In contrast to the previously studied acquired and
inducible vanA-mediated resistance observed in enterococci, the
inducible resistance we report here for S. aureus does not require
the acquisition of genes from other bacteria.
The failure of vancomycin treatment in certain S. aureus infec-
tions which, based on standard susceptibility testing, should have
been susceptible to the bactericidal effects of this antimicrobial
(i.e., VSSA strains) has been well documented (31–40). MIC ele-
vations comparable to those induced by colistin exposure have
TABLE 2 Upregulated genes in USA300 following 10-min exposure to colistina
Functional group
and gene ID no. Gene Assignment
Fold
change
Defense/stress response
SAUSA300_0835 dltA D-Alanine–poly(phosphoribitol) ligase subunit 1 3.13
SAUSA300_0836 dltB DltB protein 4.12
SAUSA300_0837 dltC D-Alanine–poly(phosphoribitol) ligase subunit 2 3.62
SAUSA300_0838 dltD D-Alanine-activating enzyme/D-alanine-D-alanyl, DltD protein 3.86
SAUSA300_1255 mprF Oxacillin resistance-related FmtC protein 3.33
SAUSA300_2573 isaB Immunodominant antigen B 3.78
Gene regulation
SAUSA300_0647 vraF ABC transporter ATP-binding protein 5.25
SAUSA300_0648 vraG ABC transporter permease 4.71
SAUSA300_1866 vraS Two-component sensor histidine kinase 1.63
SAUSA300_1865 vraR Two-component response regulator 1.54
SAUSA300_2599 tetR Intercellular adhesion operon transcription regulator (IcaR) 1.67
Metabolism
SAUSA300_0684 fruB Fructose 1-phosphate kinase 3.01
SAUSA300_1640 icd (citC) Isocitrate dehydrogenase 2.97
SAUSA300_1641 gltA Citrate synthetase 3.75
SAUSA300_2319 Pyridine nucelotide-disulfide oxidoreductase 6.26
SAUSA300_2377 Glycerate kinase 3.64
Transport
SAUSA300_1790 prsA Foldase protein PrsA 2.52
SAUSA300_2630 nixA High-affinity nickel transporter 1.81
SAUSA300_2409 nikC Oligopeptide ABC transporter permease 1.66
SAUSA300_2411 nikA Oligopeptide permease, peptide-binding protein 1.80
Miscellaneous
SAUSA300_0964 iraE Chitinase-related protein 2.35
SAUSA300_1298 Putative XpaC protein 1.64
SAUSA300_1674 htrA Putative serine protease HtrA 1.78
Hypothetical genes
SAUSA300_1606 Hypothetical protein 3.50
SAUSA300_2269 Hypothetical protein 2.18
SAUSA300_2378 Hypothetical membrane protein 1.73
SAUSA300_2493 Hypothetical exported protein 7.03
a P 0.05 for all genes listed. Boldface indicates genes that are also upregulated in clinical VISA strains.
FIG 3 Continued colistin exposure is required for cell wall gene expression.
After a 10-min colistin exposure (T0), USA300 cells were passaged in medium
with () or without () colistin. Gene expression of dltB and mprF was in-
vestigated by Northern blotting at 0, 30, 60, and 120 min after removal of
colistin from the medium. Asterisks indicate significantly different expression
levels (P 0.01, t test) between () and () cultures. Error bars represent the
standard deviations (n 3).
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been associated with increased mortality (32, 35, 37, 41). As re-
moval of colistin restored vancomycin sensitivity to the precolis-
tin level, our results raise the prospect that an infecting S. aureus
strain isolated from a patient receiving colistin may be reported as
being highly sensitive (42), whereas the actual susceptibility of
bacteria present in that patient may be reduced. However, the
gene expression alterations we have identified provide a potential
biomarker for the occurrence of reversible vancomycin resistance
in uncultured bacteria isolated from humans receiving concur-
rently administered therapeutic agents.
Our data indicate that the inducible and reversible antibiotic
tolerance may not be restricted to the colistin-vancomycin com-
bination, as several antibiotics unrelated to colistin by class and
mode of action induced reversible antibiotic tolerance toward a
variety of antibiotics. While the mechanistic details of these drug
interactions await further investigation, the inducible drug resis-
tance phenotype points to a potential need to take induced and
noninherited resistance into account when testing for antimicro-
bial susceptibility.
MATERIALS AND METHODS
Strains and growth conditions. S. aureusUSA300 FPR3757 was obtained
from the American Type Culture Collection (ATCC) and routinely grown
in Mueller-Hinton (MH) medium (Sigma) at 37°C in Erlenmeyer flasks
with aeration. A plasmid-cured version of USA300 Lac (JE2), and mutants
in this background, graR and vraR, were retrieved from The Nebraska
Transposon Mutant Library (http://www.narsa.net). JE2 was routinely
grown in MH medium at 37°C in Erlenmeyer flasks with aeration, and the
mutants were grown in the presence of 10 g/ml erythromycin except
when performing the induction experiments, in which case they were
cultured as the wild type was. For colistin induction, exposure to
150 g/ml colistin for 30 min was used unless noted otherwise.
Determination of vancomycin MICs. USA300 was grown exponen-
tially for 3 h to mid-log phase in MH before being diluted to an optical
density at 600 nm (OD600) of 0.25 in MH or MH containing 150 g/ml
colistin sodium sulfate (Sigma). Immediately after mixing (at 7, 15, and
30 min), subsamples of 5e5 CFU per ml were aliquoted into 96-well
microtiter plates containing MH and vancomycin (ranging from
0.8 g/ml to 1.8 g/ml; Sigma) as well as 150 g/ml colistin for the pre-
induced cultures. The plates were incubated at 37°C for 24 h, and growth
FIG 4 Colistin induces VISA phenotypes. (a) Assay for decreased autolysis.
Cells were grown with or without colistin for 1 h before being washed and
resuspended in buffer containing detergent. Autolysis was determined based
on the decrease in optical density over time compared to that of a control
culture with no added detergent (n 3). (b) Assay for diminished negative cell
surface charge. After growth with (shaded bars) or without (no fill) colistin
exposure for various periods of time, cells were washed and resuspended in
buffer containing the positively charged molecule cytochrome c, which binds
to the negatively charged cell surface. Differences between cultures with or
without colistin in terms of the amount of unbound cytochrome c in the
supernatant after removal of cells were measured spectrophotometrically and
used as an indicator for cell surface charge. More cytochrome c bound indi-
cates a more negatively charged cell surface (n  3). (c) Cell wall thickness.
Cells were grown with or without colistin for 1 h before being harvested and
prepared for TEM analysis. Inspection of 50 cells under each condition re-
vealed no significant difference in cell wall thickness. In all cases, error bars
represent the standard deviations.
FIG 5 Regulatory two-component systems that mediate colistin-induced
vancomycin tolerance. USA300 JE2 and derived mutants were grown in liquid
medium with (shaded bars) and without (no fill) colistin for 30 min. Subse-
quently, the colony-forming ability on plates containing inhibitory concentra-
tions of vancomycin was determined in standard plating assays. Error bars
represent the standard deviations (n 3). *, P 0.05.
Haaber et al.
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was determined by using a Tecan Infinite 200 apparatus. The MIC was
determined from the optical density measurements of 8 technical and 3
biological replicates.
Susceptibility screen. Exponential-phase cultures were adjusted to an
OD600 of 0.02 in warm MH broth, and inducer antibiotics were added at
sublethal concentrations (60 g/ml colistin sodium sulfate [Sigma],
0.001g/ml rifampin [Sigma], or 0.2g/ml ciprofloxacin [Sigma]). After
90 min at 37°C and 180 rpm, 10-l aliquots of the cultures were spotted
on freshly prepared MH agar plates containing inhibitory concentrations
of the tester antibiotic (1.5g/ml vancomycin, 360g/ml colistin sodium
sulfate, 1.125g/ml teicoplanin, 2g/ml daptomycin, 0.009g/ml rifam-
pin). The plates were incubated overnight at 37°C.
Vancomycin susceptibility testing by plating. Exponential-phase
cultures were adjusted to an OD600 of 0.25 in warm MH broth, and
150 g/ml colistin was added to one culture. After 30 min, serial 10-fold
dilutions were prepared, and 100-l aliquots of the appropriate dilutions
were plated on freshly prepared MH agar plates containing inhibitory
concentrations of vancomycin. The plates were incubated overnight at
37°C, and CFU were determined. In one experiment, the cultures were
also spotted at 0 and 30 min after removing colistin from the broth by
spinning (5,000  g, 5 min, room temperature) and resuspending in
warm MH broth.
Determination of Triton X-100-induced autolysis. The autolysis as-
say was performed as described previously (27). Briefly, strains were
grown in MH broth at 37°C, 180 rpm, to mid-exponential phase. The
cultures were diluted to an OD600 of 0.15 in warm MH, grown to an OD600
of 0.25, and 150 g/ml colistin was added to one subset while another
subset served as the nonexposed control. After 1 h, the cultured cells were
washed twice in ice-cold sterile distilled water and resuspended in the
same volume of 0.05 M Tris-HCl (pH 7.2) containing 0.05% Triton
X-100. Cells were incubated at 30°C, and the OD600 was measured every
30 min. Data are expressed as the percent loss of OD600 at the indicated
times compared to findings at time zero. Each data point represents the
mean and standard deviation from three independent experiments.
TEM. For transmission electron microscopy (TEM), strains were
grown in MH broth at 37°C, 180 rpm, to mid-exponential phase. The
cultures were diluted to an OD600 of 0.15 in warm MH, grown to an OD600
of 0.25, and 150 g/ml colistin was added. After 1 h the cultures were
harvested by low-speed centrifugation for 5 min at 0°C. The pellets were
resuspended in 10 ml of 2.5% glutaraldehyde in 0.1 M sodium cacodylate
buffer and incubated at 5°C overnight. Again, cells were harvested by
low-speed centrifugation. The pellets were resuspended in 5 ml glutaral-
dehyde and stored at 5°C. The samples where rinsed in 0.15 M sodium
cacodylate buffer (pH 7.4) and postfixed in 1% osmium tetroxide in
0.12 M sodium cacodylate buffer for 2 h at room temperature. Then, they
were dehydrated in a graded series of ethanol solutions according to stan-
dard procedures, transferred to propylene oxide, and embedded in Epon.
On one-hole copper grids, ultrathin sections of 80 nm where stained with
uranyl acetate and lead citrate. The samples were studied using a Philips
CM 100 transmission electron microscope. The mean thickness and stan-
dard deviation of at least 50 cells from each treatment condition were
determined at magnifications of 60 to 120,000 using iTEM (Olym-
pus). The cells examined were located in different fields. All cells were
intact and were visualized in full cross-section without a section artifact.
Cell wall thickness was measured from the outer aspect of the cell mem-
brane to the outer aspect of the cell wall.
Determination of whole-cell surface charges. The assay for whole-
cell surface charges was performed as described previously (16, 43).
Briefly, strains were grown in MH broth at 37°C, 180 rpm, to mid-
exponential phase with and without exposure to colistin for 1 to 4 h. To
ensure continued exponential growth during treatment, cultures were
diluted in prewarmed medium with or without colistin, thereby keeping
them in the log-phase state. After treatment, cells were harvested by cen-
trifugation (800 rpm, 2 min) and washed twice with morpholinepropane-
sulfonic acid buffer (20 mM, pH 7). The cells were resuspended in the
buffer containing 0.125 mg/ml cytochrome c (Sigma) to an approximate
OD600 of 7 and incubated at room temperature. After 10 min, the suspen-
sions were centrifuged at 8,000 rpm for 2 min. The amount of cytochrome
c remaining in the supernatant was quantified based on the OD530; this
measure is negatively correlated to the negative charge of the bacterial cell
surface. The data shown are the means and standard deviations from three
independent experiments.
RNA isolation for DNA microarray gene expression studies.
USA300 was grown exponentially for 3 h in MH before 62.5g/ml colistin
was added at an OD600 of 0.25. After 10 min of exposure, 50 ml culture was
harvested onto Whatman nitrocellulose filters and snap-frozen in liquid
nitrogen. RNA was isolated by pulverizing the filters containing bacteria
with a mortar and pestle in liquid nitrogen followed by purification using
the TRIzol (Invitrogen) procedure according to the manufacturer’s rec-
ommendations. Samples were DNase treated and cleaned using the
RNeasy (Qiagen) protocol according to the manufacturer’s recommen-
dations. RNA quantity and quality were measured on a NanoDrop ND-
1000 spectrophotometer (Thermo Scientific).
DNA microarray analysis. Approximately 10 g of total RNA was
used for the Cy3/Cy5 labeling procedure. Labeling, cDNA purification,
hybridization, and washing were performed as described previously (44),
except that USA300-specific DNA microarray slides were used (purchased
from MYcroarray). The slides were scanned in a GenePix 4000B reader
and processed using GenePix Pro software.
The slides were analyzed in R with the linear models for microarray
data (LIMMA) package. Background correction was conducted using the
normexp method (45), and normalization was conducted using the “nor-
malizeWithinArrays” method (46). Log ratios (M) and log intensities (A)
were calculated, and differential expression analysis was conducted using
the lmFit and eBayes functions (47). Genes were ranked by their adjusted
P values by using the topTable function. R scripts and specific commands
used for the analysis are available upon request. Clustering analysis was
performed by using Cluster 3.0 (48) and the hierarchical clustering of
genes method, and the clusters were visualized using Java TreeView (49).
Significance levels for overlapping genes to VISA strains were deter-
mined by calculation of the representation factor using the software at
http://nemates.org/MA/progs/representation.stats.html. A representa-
tion factor of 	1 indicated more overlap than expected between two
independent groups.
RNA isolation and quantification of transcript levels by Northern
blotting. Exponential-phase cultures were adjusted to an OD600 of 0.25 in
warm MH broth, and 150 g/ml colistin was added. At different time
points, cells were harvested by centrifugation at 8,000 rpm for 3 min. The
cells were lysed mechanically using the FastPrep system (Bio101; Qbio-
gene), and total RNA was extracted using a Qiagen RNeasy minikit ac-
cording to the manufacturer’s instructions. RNA quantity and quality
were measured on a NanoDrop ND-1000 spectrophotometer based on
the absorbance (the A260 and the A260/A280 and A260/A230 ratios, respec-
tively). Four micrograms of RNA from each preparation was loaded onto
a 1% agarose gel and transferred to a positively charged nylon membrane
(GE Healthcare). The hybridization was performed using gene-specific
probes labeled with [32P]dCTP (PerkinElmer) and Ready-to-Go DNA-
labeling beads from GE Healthcare. Internal fragments of the genes were
amplified using the following primers: graR-forward, TGCTGGTATTGA
AGATTTCG; graR-reverse, CCTACTTTTGTTTCGATTGC; vraR-
forward, GTGGATGATCATGAAATGGT; vraR-reverse, TGGAATGCA
TAGATAACAGC; mprF-forward, CTGTGGTGTAATTGTTGACG;
mprF-reverse, TAATTACCGCCGTACTGATT; dltB-forward, ACCAAC
AGGCAATGAATATC; dltB-reverse, TAAGTGCTGTTGTGAAACCA.
The PCR products were used as the templates in the labeling reactions.
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